{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:18:38Z","timestamp":1787062718643,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1779,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1111\/j.1524-4733.2008.00329.x","type":"journal-article","created":{"date-parts":[[2008,5,20]],"date-time":"2008-05-20T13:30:13Z","timestamp":1211290213000},"page":"800-808","source":"Crossref","is-referenced-by-count":16,"title":["Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA"],"prefix":"10.1016","volume":"11","author":[{"given":"Joshua A.","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Borker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily","family":"Belozeroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 Suppl. 1","key":"10.1111\/j.1524-4733.2008.00329.x_bib10","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0272-6386(00)70239-3","article-title":"Cardiovascular disease and chronic renal disease: a new paradigm","volume":"35","author":"Sarnak","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib20","series-title":"USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases","author":"U.S. Renal Data System","year":"2006"},{"issue":"5 Suppl. 3","key":"10.1111\/j.1524-4733.2008.00329.x_bib30","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib40","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1681\/ASN.2004040275","article-title":"Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study","volume":"16","author":"Slinin","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib50","first-page":"1425","article-title":"[Cardiovascular risk factors in dialyzed patients]","volume":"112","author":"Kobus","year":"2004","journal-title":"Pol Arch Med Wewn"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib60","first-page":"1","article-title":"Epidemiology of chronic kidney disease in Italy: possible therapeutical approaches","volume":"16","author":"Locatelli","year":"2003","journal-title":"J Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib70","first-page":"405","article-title":"Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease","volume":"17","author":"Buccianti","year":"2004","journal-title":"J Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib80","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/039139880302600303","article-title":"Relationship between diabetes mellitus and degree of coronary artery disease in uraemic patients investigated with coronary angiography","volume":"26","author":"Fabbian","year":"2003","journal-title":"Int J Artif Organs"},{"issue":"Suppl.","key":"10.1111\/j.1524-4733.2008.00329.x_bib90","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1111\/j.1523-1755.2005.09507.x","article-title":"Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD)","volume":"95","author":"Qunibi","year":"2005","journal-title":"Kidney Int"},{"issue":"Suppl.","key":"10.1111\/j.1524-4733.2008.00329.x_bib100","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"73","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib110","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1046\/j.1523-1755.2000.00018.x","article-title":"Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients","volume":"57","author":"Suliman","year":"2000","journal-title":"Kidney Int"},{"issue":"Suppl. 1","key":"10.1111\/j.1524-4733.2008.00329.x_bib120","first-page":"S68","article-title":"Cardiovascular risk in patients with chronic renal failure. Patients in renal replacement therapy","volume":"22","author":"Cases","year":"2002","journal-title":"Nefrologia"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/ndt\/15.4.454","article-title":"Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors?","volume":"15","author":"Zoccali","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib140","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/ndt\/gfh120","article-title":"Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography","volume":"19","author":"Haydar","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib150","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","article-title":"Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study","volume":"67","author":"Young","year":"2005","journal-title":"Kidney Int"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib160","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib170","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO (4), Ca \u00d7 PO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl.","key":"10.1111\/j.1524-4733.2008.00329.x_bib180","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1046\/j.1523-1755.63.s85.26.x","article-title":"Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population","volume":"85","author":"Marco","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/ajkd.2003.50050","article-title":"The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population","volume":"41","author":"Rubel","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000187162","article-title":"In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol","volume":"63","author":"Aparicio","year":"1993","journal-title":"Nephron"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib220","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJM198908033210502","article-title":"Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure","volume":"321","author":"Andress","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib230","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib240","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib250","series-title":"Skeletal Disorders. Oxford Textbook of Clinical Nephrology","author":"Reichel","year":"1997"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib260","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","article-title":"Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management","volume":"35","author":"Block","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib270","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/ajkd.2002.33401","article-title":"Analysis of renal bone disease treatment in dialysis patients","volume":"39","author":"Johnson","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib280","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1523-1755.2000.00819.x","article-title":"Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group","volume":"57","author":"Indridason","year":"2000","journal-title":"Kidney Int"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib290","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib300","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib310","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib320","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium \u00d7 phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib330","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib340","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","volume":"47","author":"Danese","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib350","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","article-title":"Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl","volume":"20","author":"Moe","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib360","unstructured":"Belozeroff V, Borker R, Barder B, Pupim L, Hakim RM. Trends in parathyroid hormone in hemodialysis patients. National Kidney Foundation (NKF) 2007 Spring Clinical Meeting. 2007"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib370","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib380","first-page":"461A","article-title":"Phase 3 study results demonstrate efficacy and safety of calcimimetic cinacalcet HCL in hemodialysis patients with second ary hyperparathyroidism (HPT)","volume":"14","author":"Block","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib390","first-page":"461A","article-title":"Cinacalcet HCL (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyoidism (HPT): results of a European\/Australian phase 3 study","volume":"14","author":"de Francisco","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib400","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0168-8510(98)00017-7","article-title":"Economic evaluation of end stage renal disease treatment","volume":"44","author":"de Wit","year":"1998","journal-title":"Health Policy"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib410","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jama.1995.03520390045031","article-title":"Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team","volume":"273","author":"Nease","year":"1995","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib420","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib430","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s001980200107","article-title":"A systematic review of health state utility values for osteoporosis-related conditions","volume":"13","author":"Brazier","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib440","author":"Tufts-New England Medical Center"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib450","first-page":"5","article-title":"Pharmacoeconomic guidelines around the world","volume":"10","author":"Tarn","year":"2004","journal-title":"ISPOR Connections"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib460","series-title":"Cost-Effectiveness in Health and Medicine","author":"Gold","year":"1996"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib470","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","article-title":"Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?","volume":"7","author":"Eichler","year":"2004","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib480","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.jrn.2006.04.010","article-title":"Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease","volume":"16","author":"Torres","year":"2006","journal-title":"J Ren Nutr"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib490","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/j.1523-1755.2004.00972.x","article-title":"Survival following parathyroidectomy among United States dialysis patients","volume":"66","author":"Kestenbaum","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib500","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1523-1755.2004.00436.x","article-title":"Medical control of secondary hyperparathyroidism: we're not there yet","volume":"65","author":"Goodman","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib510","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/ndt\/gfl774","article-title":"The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective","volume":"22","author":"Garside","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib520","unstructured":"Doan QV, Dylan M, Griffiths R, et al. Economic impact of cardiovascular disease and fractures in patients with ESRD. National Kidney Foundation (NKF) 2007 Spring Clinical Meeting. 2007."},{"key":"10.1111\/j.1524-4733.2008.00329.x_bib530","author":"Watkins Memorial Health Center"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510605591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510605591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T20:48:51Z","timestamp":1631306931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301510605591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S1098301510605591"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00329.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}